PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 1999 February; 79(3-4): 620–626.
PMCID: PMC2362418

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients

Abstract

Dihydropyrimidine dehydrogenase (DPD) is responsible for the breakdown of the widely used antineoplastic agent 5-fluorouracil (5FU), thereby limiting the efficacy of the therapy. To identify patients suffering from a complete or partial DPD deficiency, the activity of DPD is usually determined in peripheral blood mononuclear cells (PBM cells). In this study, we demonstrated that the highest activity of DPD was found in monocytes followed by that of lymphocytes, granulocytes and platelets, whereas no significant activity of DPD could be detected in erythrocytes. The activity of DPD in PBM cells proved to be intermediate compared with the DPD activity observed in monocytes and lymphocytes. The mean percentage of monocytes in the PBM cells obtained from cancer patients proved to be significantly higher than that observed in PBM cells obtained from healthy volunteers. Moreover, a profound positive correlation was observed between the DPD activity of PBM cells and the percentage of monocytes, thus introducing a large inter- and intrapatient variability in the activity of DPD and hindering the detection of patients with a partial DPD deficiency. © 1999 Cancer Research Campaign

Keywords: dihydropyrimidine dehydrogenase, 5-fluorouracil, cancer, blood cells, patients

Full Text

The Full Text of this article is available as a PDF (91K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol. 1996 Dec;14(12):3085–3096. [PubMed]
  • Cany L, Toulouse C, Ravaud A, Durand M, Mauriac L. Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases. Eur J Cancer. 1996 Feb;32A(2):370–371. [PubMed]
  • Born J, Lange T, Hansen K, Mölle M, Fehm HL. Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol. 1997 May 1;158(9):4454–4464. [PubMed]
  • Chazal M, Etienne MC, Renée N, Bourgeon A, Richelme H, Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res. 1996 Mar;2(3):507–510. [PubMed]
  • de Boer M, Roos D. Metabolic comparison between basophils and other leukocytes from human blood. J Immunol. 1986 May 1;136(9):3447–3454. [PubMed]
  • de Korte D, Haverkort WA, van Gennip AH, Roos D. Nucleotide profiles of normal human blood cells determined by high-performance liquid chromatography. Anal Biochem. 1985 May 15;147(1):197–209. [PubMed]
  • Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée N, Schneider M, Demard F, Milano G. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994 Nov;12(11):2248–2253. [PubMed]
  • Fernandez-Salguero P, Gonzalez FJ, Etienne MC, Milano G, Kimura S. Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes. Biochem Pharmacol. 1995 Sep 28;50(7):1015–1020. [PubMed]
  • Fleming RA, Milano G, Thyss A, Etienne MC, Renée N, Schneider M, Demard F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992 May 15;52(10):2899–2902. [PubMed]
  • Fleming RA, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R, Renée N, Schneider M, Demard F. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer. 1993;29A(5):740–744. [PubMed]
  • Grem JL, Yee LK, Venzon DJ, Takimoto CH, Allegra CJ. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol. 1997;40(2):117–125. [PubMed]
  • Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990 Jan 1;50(1):197–201. [PubMed]
  • Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer. 1991 Aug 1;68(3):499–501. [PubMed]
  • Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987 Apr 15;47(8):2203–2206. [PubMed]
  • Ho DH, Townsend L, Luna MA, Bodey GP. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res. 1986 Jul-Aug;6(4):781–784. [PubMed]
  • Kaffenberger W, Hölzer-Müller L, Auberger T, Clasen BP, Hohlmeier G, van Beuningen D. An immunological outcome predictive score for head and neck carcinoma patients. Strahlenther Onkol. 1995 Aug;171(8):444–453. [PubMed]
  • Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993 Nov 15;53(22):5433–5438. [PubMed]
  • Lyss AP, Lilenbaum RC, Harris BE, Diasio RB. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest. 1993;11(2):239–240. [PubMed]
  • Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL, Gress RE. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994 Oct 1;84(7):2221–2228. [PubMed]
  • MALDONADO JE, HANLON DG. MONOCYTOSIS: A CURRENT APPRAISAL. Mayo Clin Proc. 1965 Mar;40:248–259. [PubMed]
  • McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol. 1996 May;41(5):425–427. [PMC free article] [PubMed]
  • Milano G, Etienne MC. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). Anticancer Res. 1994 Nov-Dec;14(6A):2295–2297. [PubMed]
  • Milano G, Etienne MC. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics. 1994 Dec;4(6):301–306. [PubMed]
  • Pero RW, Johnson D, Olsson A. Catabolism of exogenously supplied thymidine to thymine and dihydrothymine by platelets in human peripheral blood. Cancer Res. 1984 Nov;44(11):4955–4961. [PubMed]
  • Spector T, Harrington JA, Porter DJ. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol. 1993 Dec 14;46(12):2243–2248. [PubMed]
  • Stéphan F, Etienne MC, Wallays C, Milano G, Clergue F. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med. 1995 Dec;99(6):685–688. [PubMed]
  • Strender LE, Blomgren H, Petrini B, Wasserman J, Forsgren M, Norberg R, Baral E, Wallgren A. Immunologic monitoring in breast cancer patients receiving postoperative adjuvant chemotherapy. Cancer. 1981 Nov 1;48(9):1996–2002. [PubMed]
  • Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR, Jr, Grem JL, Allegra CJ, Diasio RB, Chu E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996 Mar;2(3):477–481. [PubMed]
  • Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML, Mirkin BL. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med. 1985 Jul 25;313(4):245–249. [PubMed]
  • van Gennip AH, Busch S, Elzinga L, Stroomer AE, van Cruchten A, Scholten EG, Abeling NG. Application of simple chromatographic methods for the diagnosis of defects in pyrimidine degradation. Clin Chem. 1993 Mar;39(3):380–385. [PubMed]
  • van Gennip AH, Abeling NG, Stroomer AE, van Lenthe H, Bakker HD. Clinical and biochemical findings in six patients with pyrimidine degradation defects. J Inherit Metab Dis. 1994;17(1):130–132. [PubMed]
  • van Gennip AH, Abeling NG, Vreken P, van Kuilenburg AB. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherit Metab Dis. 1997 Jun;20(2):203–213. [PubMed]
  • Van Kuilenburg AB, Van Lenthe H, Van Gennip AH. Identification and tissue-specific expression of a NADH-dependent activity of dihydropyrimidine dehydrogenase in man. Anticancer Res. 1996 Jan-Feb;16(1):389–394. [PubMed]
  • Van Kuilenburg AB, Vreken P, Beex LV, Meinsma R, Van Lenthe H, De Abreu RA, van Gennip AH. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer. 1997 Nov;33(13):2258–2264. [PubMed]
  • Van Kuilenburg AB, Van Lenthe H, Wanders RJ, Van Gennip AH. Subcellular localization of dihydropyrimidine dehydrogenase. Biol Chem. 1997 Sep;378(9):1047–1053. [PubMed]
  • Van Kuilenburg AB, Vreken P, Beex LV, Meinsma R, Van Lenthe H, De Abreu RA, Van Gennip AH. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Adv Exp Med Biol. 1998;431:293–298. [PubMed]
  • Van Kuilenburg AB, Van Lenthe H, Wanders RJ, Van Gennip AH. Subcellular localization of dihydropyrimidine dehydrogenase. Adv Exp Med Biol. 1998;431:817–821. [PubMed]
  • Van Kuilenburg AB, Poorter RL, Peters GJ, Van Gennip AH, Van Lenthe H, Stroomer AE, Smid K, Noordhuis P, Bakker PJ, Veenhof CH. No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil. Adv Exp Med Biol. 1998;431:811–816. [PubMed]
  • Vreken P, Van Kuilenburg AB, Meinsma R, Smit GP, Bakker HD, De Abreu RA, van Gennip AH. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis. 1996;19(5):645–654. [PubMed]
  • Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH. Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene. J Inherit Metab Dis. 1997 Jul;20(3):335–338. [PubMed]
  • Vreken P, Van Kuilenburg AB, Meinsma R, De Abreu RA, Van Gennip AH. Identification of a four-base deletion (delTCAT296-299) in the dihydropyrimidine dehydrogenase gene with variable clinical expression. Hum Genet. 1997 Aug;100(2):263–265. [PubMed]
  • Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996 Aug 1;98(3):610–615. [PMC free article] [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK